Eribulin mesylate is a microtubule targeting agent that is used in the treatment of metastatic breast cancer. It inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
Description :
Eribulin mesylate (B1939, E7389, ER-086526) is a macrocyclic ketone analogue of halichondrir B, shows sub-nM growth inhibitory activities in vitro against numerous human cancer cell lines via inhibition of tubulin polymerization; induces G2-M cell cycle arrest and disruption of mitotic spindles, demonstrates marked in vivo activities at 0.1-1 mg/kg against human xenografts: MDA-MB-435 breast cancer, COLO 205 colon cancer, LOX melanoma, and NIH: OVCAR-3 ovarian cancer.